Avivagen Terminates Exclusive U.S. Sales and Distribution Agreement

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced that it has terminated its sales and distribution agreement with CSA Animal Nutrition in the United States.

“We’ve seen demand for OxC-beta^TM Livestock grow rapidly in key markets across Asia and throughout Mexico, and will be looking to replicate that same corporate strategy and success in the United States moving forward,” said Kym Anthony, Chief Executive Officer, Avivagen Inc. “We appreciate all of CSA’s efforts on Avivagen’s behalf over the past few years.”

With production of 215 million tonnes of livestock feed in 2020, the United States accounts for 18% of the world’s 1.19 Billion tonne global livestock feed market.ⁱ

About OxC-beta Technology and OxC-beta Livestock
Avivagen’s OxC-beta technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia and Malaysia.

Avivagen’s OxC-beta Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

About Avivagen
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.